

Terry D Butters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4950098/publications.pdf>

Version: 2024-02-01

25
papers

1,535
citations

567144

15
h-index

642610

23
g-index

25
all docs

25
docs citations

25
times ranked

1765
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting glycosylation as a therapeutic approach. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 65-75.	21.5	409
2	Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. <i>Glycobiology</i> , 2005, 15, 43R-52R.	1.3	204
3	Therapeutic Applications of Imino Sugars in Lysosomal Storage Disorders. <i>Current Topics in Medicinal Chemistry</i> , 2003, 3, 561-574.	1.0	156
4	Crystal Structures of Complexes of N-Butyl- and N-Nonyl-Deoxynojirimycin Bound to Acid β -Glucosidase. <i>Journal of Biological Chemistry</i> , 2007, 282, 29052-29058.	1.6	109
5	Gaucher disease. <i>Current Opinion in Chemical Biology</i> , 2007, 11, 412-418.	2.8	109
6	Introduction: Glycobiology Understanding the Language and Meaning of Carbohydrates. <i>Chemical Reviews</i> , 2002, 102, 283-284.	23.0	92
7	Evidence That N-Linked Glycosylation Is Necessary for Hepatitis B Virus Secretion. <i>Virology</i> , 1995, 213, 660-665.	1.1	88
8	Structural and mechanistic insight into N-glycan processing by endo- β -mannosidase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 781-786.	3.3	74
9	Small molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2003, 358, 927-945.	1.8	58
10	Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 427-435.	0.9	44
11	Inhibitors of Glycosphingolipid Biosynthesis.. <i>Trends in Glycoscience and Glycotechnology</i> , 1995, 7, 495-511.	0.0	38
12	Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca ²⁺ stores. <i>Virology</i> , 2014, 462-463, 135-148.	1.1	32
13	Synthesis of 1,5-dideoxy-3-O-(β -D-mannopyranosyl)-1,5-imino-D-mannitol and 1,5-dideoxy-3-O-(β -D-glucopyranosyl)-1,5-imino-D-mannitol: Powerful inhibitors of endomannosidase. <i>Tetrahedron: Asymmetry</i> , 1993, 4, 2011-2024.	1.8	22
14	Glycoprotein misfolding in the endoplasmic reticulum: identification of released oligosaccharides reveals a second ER-associated degradation pathway for Golgi-retrieved proteins. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 2799-2814.	2.4	20
15	Novel mannosidase inhibitors probe glycoprotein degradation pathways in cells. <i>Glycoconjugate Journal</i> , 2009, 26, 1109-1116.	1.4	19
16	Structural characterization of the N-linked oligosaccharides derived from HIVgp120 expressed in lepidopteran cells. <i>Glycoconjugate Journal</i> , 1998, 15, 83-88.	1.4	16
17	Structure of human endo- β -1,2-mannosidase (MANEA), an antiviral host-glycosylation target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29595-29601.	3.3	14
18	Substrate deprivation: A new therapeutic approach for the glycosphingolipid lysosomal storage diseases. <i>Expert Reviews in Molecular Medicine</i> , 2000, 2, 1-17.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Restricted processing of glycans by endomannosidase in mammalian cells. <i>Glycobiology</i> , 2012, 22, 1282-1288.	1.3	9
20	Inhibition of α -glucosidase activity by N-deoxynojirimycin analogs in several insect phloem sap feeders. <i>Insect Science</i> , 2016, 23, 59-67.	1.5	5
21	Ultrastructural changes in the Golgi apparatus and secretory granules of HL-60 cells treated with the imino sugar N-butyldeoxynojirimycin. <i>Biology of the Cell</i> , 1997, 89, 123-131.	0.7	3
22	Miglustat. <i>Drugs</i> , 2003, 63, 2435-2436.	4.9	1
23	Ultrastructural changes in the Golgi apparatus and secretory granules of HL-60 cells treated with the imino sugar N-butyldeoxynojirimycin. <i>Biology of the Cell</i> , 1997, 89, 123-131.	0.7	1
24	Substrate reduction therapy in lysosomal storage diseases: a clarification. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 98-98.	21.5	0
25	Miglustat: profile report. <i>Drugs and Therapy Perspectives</i> , 2004, 20, 5-7.	0.3	0